financetom
Business
financetom
/
Business
/
DBS sees rising demand for yuan settlements from Chinese exporters
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DBS sees rising demand for yuan settlements from Chinese exporters
Aug 12, 2025 11:18 PM

SINGAPORE (Reuters) -DBS Group, Southeast Asia's largest lender by assets, is seeing growing interest from Chinese exporters to settle trades in renminbi (RMB), or yuan, particularly with counterparts in Latin America and the Middle East, a senior executive said.

"Right now, you see the Chinese exporters, some are beginning to ask and say, I'm going to sell in RMB, please settle in RMB," said Han Kwee Juan, speaking to Reuters in his first media interview since becoming DBS's group head of institutional banking in January.

"Is that a trend that will continue? I think that it's something that they will continue to ask for as they trade more with the rest of the world, outside of the U.S.," he said.

The shift comes as decades of unwavering faith in the U.S. dollar's dominance in global trade and capital flows faces scrutiny. Major emerging market economies are stepping up efforts to trade in local currencies, underscoring efforts to reduce reliance on the dollar in the global financial system.

However, Han said that most settlements outside of China remain "largely in dollars".

The bank's subsidiary, DBS China, has been a member of China's Cross-Border Interbank Payment System (CIPS) since 2015.

China launched CIPS in 2015 to promote the yuan's usage in international trade. It allows global banks to clear cross-border yuan transactions directly onshore, instead of through clearing banks in offshore yuan hubs.

DBS's settlement flows through the CIPS clearing system grew 30% year-on-year in 2024, Han said, though he maintained that the shift toward more yuan-denominated settlements remains gradual.

In a wide-ranging interview, Han spoke of how businesses are dealing with the uncertainty over Trump's tariffs and outlined DBS's growth strategy in the current economic environment.

"One of the things that we have been growing this year is we have been growing our capability for FI clearing," he said.

"We have been quite purposeful in terms of investment that we have made in the clearing capabilities."

The bank is also looking to capitalise on its institutional banking business to drive its return on equity, which currently stands at 17%, Han said. Last week, DBS posted a quarterly profit that beat estimates, sending its shares to a record high.

"By being able to work with the customers holistically, not just with lending, but also with advisory and as well as cash management, enables us to not only just look at lending or (net interest income) as a source of revenue, but really growing our fee-based revenues," Han said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US says FAA oversight of Boeing production 'not effective'
US says FAA oversight of Boeing production 'not effective'
Oct 11, 2024
* FAA's audit processes not comprehensive enough, says report * FAA agrees with 16 recommendations to improve oversight * FAA has not enforced timely resolution of undue pressure allegations By David Shepardson WASHINGTON, Oct 11 (Reuters) - A federal watchdog on Friday criticized the Federal Aviation Administration's oversight of Boeing ( BA ) airplane production, saying it does not have...
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Oct 11, 2024
Perspective Therapeutics, Inc. ( CATX ) is down 13% at $11.53 at last check Friday. The downtrend comes as initial results from its study of [212Pb]VMT01 are set to be presented to the International Congress of the Society for Melanoma Research. VMT01 is a MC1R-targeted radiopharmaceutical therapy (RPT) that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments or 212Pb...
Eni CEO says U.S. funds are showing confidence in group's strategy
Eni CEO says U.S. funds are showing confidence in group's strategy
Oct 11, 2024
MILAN (Reuters) - U.S. investment funds are showing confidence in Eni's strategy of spinning off growth businesses in order to attract financial resources, the Italian energy group's CEO Claudio Descalzi said on Friday. Under its so-called 'satellite' strategy, Eni has created several companies dedicated to low-carbon businesses and upstream assets and is currently in talks with U.S. fund KKR to...
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
Oct 11, 2024
On Friday, Capricor Therapeutics ( CAPR ) announced 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive muscle weakness and degeneration.  Cardiac and orthopedic complications, including scoliosis and contractures (tightened muscles)  The data was highlighted at...
Copyright 2023-2026 - www.financetom.com All Rights Reserved